Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 16/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14841024 | 0.91 | CYP46A1 (1.00) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL30595268 | 0.90 | CYP46A1 (0.68) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL24484750 | 0.90 | CYP46A1 (0.68) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849085 | 0.90 | CYP46A1 (0.76) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL26081037 | 0.90 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840555 | 0.88 | CYP46A1 (0.79) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14849031 | 0.87 | CYP46A1 (0.85) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840843 | 0.87 | CYP46A1 (0.83) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL14840592 | 0.87 | CYP46A1 (0.69) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL22719357 | 0.87 | CYP46A1 (0.64) | CYP46A1CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-11-16 | — | — | US | claimed |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2021-07-08 | — | — | US | claimed |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-07-21 | — | — | US | claimed |
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-05-21 | — | — | US | claimed |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-04 | — | — | US | claimed |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-01 | — | — | US | claimed |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-30 | — | — | US | claimed |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2019-03-07 | — | — | US | claimed |
| EP-2763979-B1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2018-12-26 | — | — | EP | claimed |
| US-10144743-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-12-04 | — | — | US | claimed |
| US-9586930-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-07 | — | — | US | claimed |
| US-20160326136-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICALS CO (JP) | 2016-11-10 | — | — | US | claimed |
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-31 | — | — | US | claimed |
| US-8871766-B2 | Heterocyclic compounds | TAKEDA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-28 | — | — | US | claimed |
| US-20140228373-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | claimed |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-27 | — | — | US | claimed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | claimed |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200157117-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20150376205-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN1, HTT | CYP46A1 3483/4885CYP3A4 4115/4885CYP2C8 4700/4885 |
| US-20190233436-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | CYP46A1 1/4885CYP3A4 26/4885CYP2C8 64/4885 |
| US-10273245-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20160326136-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-11174272-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-10144743-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20140228373-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, PSEN1, HTT | CYP46A1 3483/4885CYP3A4 4115/4885CYP2C8 4700/4885 |
| US-10717748-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20140088118-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | CYP46A1 1579/4885CYP3A4 3310/4885CYP2C8 3312/4885 |
| US-20130090341-A1 | HETEROCYCLIC COMPOUNDS | HTT, NQO1, BDNF | CYP46A1 1579/4885CYP3A4 3310/4885CYP2C8 3312/4885 |
| US-10550129-B2 | 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20190071455-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
| US-20210206781-A1 | 1-ARYLCARBONYL-4-OXY-PIPERIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PSEN1 | CYP46A1 3780/4885CYP3A4 4375/4885CYP2C8 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.